A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium.
about
Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumorsRedox-directed cancer therapeutics: molecular mechanisms and opportunitiesPharmacology of iron transportStructure-antiproliferative activity studies on l-proline- and homoproline-4-N-pyrrolidine-3-thiosemicarbazone hybrids and their nickel(ii), palladium(ii) and copper(ii) complexes.Copper(ii) thiosemicarbazone complexes induce marked ROS accumulation and promote nrf2-mediated antioxidant response in highly resistant breast cancer cells.Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancerA phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients.A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.The way forward in treating pancreatic cancerExploring the anti-cancer activity of novel thiosemicarbazones generated through the combination of retro-fragments: dissection of critical structure-activity relationships.Strong effect of copper(II) coordination on antiproliferative activity of thiosemicarbazone-piperazine and thiosemicarbazone-morpholine hybrids.Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy.Targeting cancer by binding iron: Dissecting cellular signaling pathwaysLymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic CancerFluorescence properties and cellular distribution of the investigational anticancer drug triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) and its zinc(II) complex.Iron Chelators and Exogenic Photosensitizers. Synergy through Oxidative Stress Gene Expression.Kinetic studies on the oxidation of oxyhemoglobin by biologically active iron thiosemicarbazone complexes: relevance to iron-chelator-induced methemoglobinemia.PAN-811 prevents chemotherapy-induced cognitive impairment and preserves neurogenesis in the hippocampus of adult rats.Piperazinyl fragment improves anticancer activity of Triapine.The role of oxidative stress in activity of anticancer thiosemicarbazones.
P2860
Q24616065-1DE3D2B2-ABFC-413A-9C73-E575CDB0BB2CQ24645584-3C6E5249-D052-4EAC-84D0-E16115E48C22Q27009387-EF61EFA8-02BE-468E-9F86-1C84C654CDE6Q31119195-156BBF78-8F1F-42CA-AA81-87514CE846E6Q31172464-46608BC5-8947-49FF-925C-024EF8540940Q33392476-11929B48-9A44-4AE0-973C-E31DBA8A9783Q33402598-289C403B-9AF8-4FF1-8827-56A372525DB8Q34685780-35890F7E-3476-45EA-8FEC-9D248CA72953Q34750537-9C549DBA-CBC0-421C-976B-B1463EE50DBAQ35076255-1230C823-BA49-4DC8-B343-BCC3635F01D6Q35348485-1599359C-3D8F-4C26-A148-496F313779AEQ35610388-C17F0D15-5D33-464A-AC08-668B454F1372Q35657936-941A5CFD-F35B-4773-944D-26A71CD88B42Q36326247-7116F7E9-B5F8-4383-B8F6-F7497D8DA73FQ36842981-1FBE48A8-3024-48C0-A1F7-F722AF0B71E5Q39753374-9EA59BC2-D77A-4FCD-B269-E59D753994C6Q41439828-5D17C634-89B4-4176-AFD8-8A1A40F18A64Q46044542-D4B8615D-91B1-4BAE-8327-ECFF7A36A02FQ48165375-7C07A9C1-A1BA-4CCC-B341-96088488D3D6Q52589888-3164ADEC-64AE-4A1D-8E57-7E17FF60DB5FQ52715779-67D6E510-8CB7-4AFF-BAE9-9ABCA07537B9
P2860
A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A Phase II study of 3-aminopyr ...... hospital Phase II consortium.
@ast
A Phase II study of 3-aminopyr ...... hospital Phase II consortium.
@en
type
label
A Phase II study of 3-aminopyr ...... hospital Phase II consortium.
@ast
A Phase II study of 3-aminopyr ...... hospital Phase II consortium.
@en
prefLabel
A Phase II study of 3-aminopyr ...... hospital Phase II consortium.
@ast
A Phase II study of 3-aminopyr ...... hospital Phase II consortium.
@en
P2093
P1476
A Phase II study of 3-aminopyr ...... hospital Phase II consortium.
@en
P2093
M J Mackenzie
P2888
P304
P356
10.1007/S10637-007-9066-3
P577
2007-06-22T00:00:00Z
P6179
1038940158